Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Terns Pharmaceuticals Inc
(NQ:
TERN
)
5.440
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Terns Pharmaceuticals Inc
< Previous
1
2
Next >
Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
June 26, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
June 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
May 25, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
May 24, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
May 22, 2023
TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
May 15, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference
May 09, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 27, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
March 27, 2023
Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
March 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
February 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 23, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Announces Pricing of $75 Million Public Offering
December 20, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Announces Proposed Public Offering
December 19, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit
December 01, 2022
Highlighting TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor to treat chronic myeloid leukemia
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 09, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
November 04, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022
October 26, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
July 27, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.